Sernova Corp.  

(Public, CVE:SVA)   Watch this stock  
Find more results for SVA
-0.010 (-6.25%)
Nov 21 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.15 - 0.15
52 week 0.10 - 0.34
Open 0.15
Vol / Avg. 51,225.00/64,486.00
Mkt cap 19.72M
P/E     -
Div/yield     -
EPS -0.02
Shares 131.48M
Beta 0.91
Inst. own     -

Key stats and ratios

Q3 (Jul '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -61.06% -32.18%
Return on average equity -63.70% -33.14%
CDP Score - -


Ste 114, 700 Collip Circle
+1-519-8585184 (Phone)
+1-519-8585099 (Fax)

Website links


Sernova Corp. is a Canada-based health sciences company focused on commercializing medical technologies. The Company is developing a platform technology for a range of disease indications, starting with a treatment for insulin-dependent diabetes, using the Cell Pouch System, a medical device for transplantation and long-term support of therapeutic cells, and its Sertolin cell technology, which provides local immune protection of therapeutic cells. Cell Pouch is a subcutaneous implantable medical device, to solve a range of issues arising from portal vein delivery. The Cell Pouch provides a natural setting for the islets where they reside in a tissue matrix with micro-vessels growing adjacent to and into the islets, which are then nourished naturally. It is evaluating the Cell Pouch System, in a tiered product development approach, including testing autograft islets (i.e., an individual�s own islets) placed in the Cell Pouch in patients with chronic pancreatitis.

Officers and directors

George Adams Independent Chairman of the Board
Philip M. Toleikis President, Chief Executive Officer, Director
Cathy R. Steiner CPA Chief Financial Officer
Frank A. Holler Director
Age: 57
James T. Parsons Director
Bruce Weber Director
Jeffrey A. Bacha Independent Director